| Literature DB >> 28480078 |
Patricia A Hageman1, Carol H Pullen2, Melody Hertzog3, Bunny Pozehl3, Christine Eisenhauer4, Linda S Boeckner5.
Abstract
Objective. This trial compared the effectiveness of a web-based only (WO) intervention with web-based supplemented by peer-led discussion (WD) or professional email counseling (WE) across 3 phases to achieve weight loss and weight maintenance in women from underserved rural communities. Methods. 301 women (BMI of 28-45 kg/m2) randomly assigned to groups participated in guided weight loss (baseline to 6 months), guided weight loss and maintenance (6 to 18 months), and self-managed weight maintenance (18 to 30 months). Results. Retention was 88.7%, 76.5%, and 71.8% at 6, 18, and 30 months, respectively. Intent-to-treat analyses demonstrated no group differences in change in weight within any phases. At 6 months, observed mean (SD) weight loss was 5.1 (6.0) kg in WO, 4.1 (5.6) kg in WD, and 6.0 (6.3) kg in WE, with 42%, 38%, and 51%, respectively, meeting ≥ 5% weight loss. These proportions dropped by a third after phase 2 with no further change during phase 3. Conclusion. Web-based interventions assisted women from rural communities in achieving 6-month weight loss, with weight regain by half at 30 months. No group differences were potentially due to the robust nature of the web-based intervention. Trial Registration. This trial is registered with ClinicalTrials.gov NCT01307644.Entities:
Mesh:
Year: 2017 PMID: 28480078 PMCID: PMC5396444 DOI: 10.1155/2017/1602627
Source DB: PubMed Journal: J Obes ISSN: 2090-0708
Summary of web-based interventions delivered to web-based only (WO) group, web-based with peer-led discussion (WD) group, and web-based with professional email counseling (WE) group.
| Group | Phase 1 (baseline to 6 months) | Phase 2 (6 to 18 Months) | Phase 3 (18 to 30 Months) |
|---|---|---|---|
| All Groups |
|
|
|
| Lifestyle weight loss plana,b | Lifestyle weight maintenance added | Preventing weight regain | |
|
|
|
| |
| ≥5 to 10% loss initial bodyweight | ≥5–10% weight loss from baseline or maintenance without regain | ≥5–10% weight loss from baseline or maintenance without regain | |
|
|
|
| |
| Weight logging daily | Weight logging weekly | Weight logging weekly encouraged | |
|
|
|
| |
| Feedback from baseline, 3- and 6-month assessments provided online | Feedback from 12- and 18-month assessments provided online | Feedback from 24- and 30-month assessments provided online | |
|
| |||
| WD only |
|
|
|
| Peer-led asynchronous discussion with weekly primers posted by peer | Peer-led asynchronous discussion with | Access to discussion board with only three primers posted by peer-leader | |
|
| |||
| WE only |
|
|
|
| Weekly feedback on women's postings | Biweekly feedback on women's postings from 6 to 12 months and once monthly during months 12 to 18 | No counselor feedback on postings is provided | |
aUS Department of Health and Human Services and US Department of Agriculture, Dietary Guidelines for Americans 2010.
bOffice of Disease Prevention and Health Promotion, 2008 Physical Activity Guidelines for Americans.
cNetzer CT, The Complete Book of Food Counts, 8th Ed., Dell Publishing Company, 2008.
Study aims, with primary and secondary outcomes, instrumentation, and assessment time points.
| Variable | Instrument | Assessment time point | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Base | 3 | 6 | 9 | 12 | 18 | 24 | 30 | ||
|
| |||||||||
| Primary outcomes | |||||||||
| Body weight (kg) | Tanita scale (TBF 215) | X | X | X | X | X | X | X | X |
| Waist circumference (cm) | Tape measure | X | X | X | X | X | X | X | X |
| Secondary outcomes | |||||||||
| Proportion achieving at least 5% weight loss | Tanita scale (TBF 215) | X | X | X | |||||
| Proportion achieving at least 10% weight loss | Tanita scale (TBF 215) | X | X | X | |||||
|
| |||||||||
| Primary outcomes | |||||||||
| Kcal intake daily | Web-version Block Health Habit and History Questionnaire | ||||||||
| X | X | X | X | ||||||
| Weekly minutes moderate or greater intensity activity | Actigraph Model GT3X Accelerometer | X | X | X | X | ||||
| Weekly minutes moderate or greater intensity activity | Survey (BRFSS) | X | X | X | X | X | X | X | X |
| Systolic blood pressure (mmHg) | Automatic Sphygmomanometer ADC e-sphyg™ 2 Model 9002 | ||||||||
| X | X | X | X | X | X | X | X | ||
| Diastolic blood pressure (mmHg) | Automatic Sphygmomanometer ADC e-sphyg 2 Model 9002 | X | X | X | X | X | X | X | X |
| Total cholesterol (mL/dL) | Chemical blood analysis | X | X | X | X | ||||
| HDL (mL/dL) | Chemical blood analysis | X | X | X | X | ||||
| LDL (mL/dL) | Chemical blood analysis | X | X | X | X | ||||
| Triglycerides (mL/dL) | Chemical blood analysis | X | X | X | X | ||||
| Fasting glucose (mL/dL) | Chemical blood analysis | X | X | X | X | ||||
| Secondary outcomes | |||||||||
| Proportion achieving 20–35% calories from fat | Web-version Block Health Habit and History Questionnaire | X | X | X | X | ||||
| Proportion achieving ≥ 150 minutes weekly moderate or greater intensity activity | Actigraph Model GT3X Accelerometer | X | X | X | X | ||||
Figure 1Participant flow diagram of the Women Weigh-in for Wellness clinical trial.
Baseline characteristics of rural women by randomized group.
| Variable | Web-based | Web-based | Web-based email (WE) | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
|
| % |
| % |
| % | |
| Race or ethnicity | ||||||
| White | 99 | 98% | 98 | 98% | 96 | 96% |
| Hispanic | 1 | 1% | 1 | 1% | 1 | 1% |
| Other | 1 | 1% | 1 | 1% | 2 | 1% |
| No response | 0 | 0% | 0 | 0% | 1 | 1% |
| Education | ||||||
| High school or lower | 20 | 20% | 12 | 12% | 15 | 15% |
| Some college | 45 | 45% | 45 | 45% | 41 | 41% |
| College grad or above | 36 | 35% | 43 | 43% | 44 | 44% |
| Employment | ||||||
| Full time | 67 | 66% | 63 | 63% | 77 | 77% |
| Part time | 18 | 18% | 26 | 26% | 9 | 9% |
| Household income | ||||||
| <$20,000 | 1 | 1% | 4 | 4% | 3 | 3% |
| $20,000 to $39,999 | 15 | 15% | 15 | 15% | 13 | 13% |
| $40,000 to $59,999 | 25 | 25% | 26 | 26% | 27 | 27% |
| $60,000 or higher | 52 | 52% | 49 | 49% | 51 | 51% |
| Rural residency | ||||||
| Large rural | 56 | 55% | 63 | 63% | 70 | 70% |
| Small rural | 10 | 10% | 10 | 10% | 4 | 4% |
| Isolated | 33 | 33% | 27 | 27% | 26 | 26% |
| Comorbid conditions | ||||||
| Diabetes | 3 | 3% | 5 | 5% | 6 | 6% |
| Respiratory | 6 | 6% | 5 | 5% | 7 | 7% |
| Arthritis | 28 | 28% | 21 | 21% | 31 | 31% |
| Other muscular conditions | 7 | 7% | 10 | 10% | 15 | 15% |
| Cancer | 11 | 11% | 9 | 9% | 7 | 7% |
| Thyroid | 28 | 28% | 20 | 20% | 22 | 22% |
| Cardiovascular | 3 | 3% | 1 | 1% | 4 | 4% |
| General | 34 | 34% | 40 | 40% | 31 | 31% |
| Smoking cigarettes | 1 | 1% | 4 | 4% | 7 | 7% |
| General health | ||||||
| Excellent to very good | 38 | 38% | 26 | 26% | 40 | 40% |
| Good | 54 | 54% | 60 | 60% | 47 | 47% |
| Poor to fair | 9 | 9% | 13 | 13% | 13 | 13% |
| BMI category (kg/m2) | ||||||
| Overweight (25–29.9) | 12 | 12% | 7 | 7% | 13 | 13% |
| Obese I (30–34.9) | 50 | 50% | 49 | 49% | 44 | 44% |
| Obese II (35–39.9) | 24 | 24% | 30 | 30% | 31 | 31% |
| Obese III (≥40 to 45) | 15 | 15% | 14 | 14% | 12 | 12% |
Observed means of primary outcome measures of intervention groups.
| Variable | Web-based | Web-based | Web-based | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
|
| Mean (SD) |
| Mean (SD) |
| Mean (SD) | |
| Body weight (kg) | ||||||
| Baseline | 101 | 93.6 (13.7) | 100 | 94.5 (12.9) | 100 | 93.3 (12.6) |
| 6 months | 87 | 88.0 (14.6) | 88 | 89.4 (13.9) | 92 | 87.2 (13.5) |
| 18 months | 81 | 88.9 (14.8) | 72 | 89.6 (13.6) | 77 | 88.3 (15.5) |
| 30 months | 76 | 89.4 (14.0) | 67 | 90.4 (13.3) | 73 | 89.5 (16.7) |
| Waist circumference (cm) | ||||||
| Baseline | 101 | 109.4 (11.6) | 100 | 108.8 (10.9) | 100 | 108.5 (10.0) |
| 6 months | 87 | 102.8 (12.1) | 88 | 103.3 (11.6) | 91 | 102.4 (11.2) |
| 18 months | 81 | 104.4 (12.0) | 71 | 104.1 (11.3) | 75 | 103.8 (13.4) |
| 30 months | 76 | 103.8 (12.0) | 66 | 103.8 (10.6) | 73 | 104.3 (13.6) |
| Kcal intake daily | ||||||
| Baseline | 101 | 1809 (729) | 100 | 1930 (675) | 100 | 1789 (556) |
| 6 months | 85 | 1516 (535) | 88 | 1514 (513) | 91 | 1415 (447) |
| 18 months | 79 | 1532 (587) | 70 | 1527 (610) | 73 | 1371 (534) |
| 30 months | 75 | 1473 (499) | 65 | 1384 (434) | 72 | 1375 (511) |
| Weekly minutes ≥ moderate intensity activity (Actigraph) | ||||||
| Baseline | 100 | 274.6 (149.6) | 99 | 252.0 (125.0) | 100 | 227.2 (137.3) |
| 6 months | 86 | 299.1 (165.3) | 84 | 273.0 (154.5) | 87 | 239.2 (126.0) |
| 18 months | 78 | 260.3 (133.5) | 71 | 251.8 (137.7) | 72 | 219.6 (113.3) |
| 30 months | 72 | 267.3 (133.1) | 65 | 248.4 (150.6) | 68 | 231.5 (131.0) |
| Weekly minutes ≥ moderate intensity activity (BRFSS) | ||||||
| Baseline | 101 | 127.8 (197.9) | 100 | 104.4 (135.6) | 100 | 109.7 (139.6) |
| 6 months | 87 | 183.9 (232.1) | 88 | 133.4 (172.5) | 91 | 171.2 (274.7) |
| 18 months | 81 | 123.6 (146.5) | 71 | 125.1 (188.4) | 75 | 125.9 (186.2) |
| 30 months | 76 | 119.4 (160.8) | 66 | 108.0 (171.2) | 73 | 100.4 (131.1 |
| Systolic blood pressure (mmHg) | ||||||
| Baseline | 101 | 123.4 (12.6) | 100 | 121.4 (10.9) | 100 | 124.4 (12.3) |
| 6 months | 87 | 120.5 (16.3) | 88 | 120.1 (12.5) | 91 | 120.6 (13.0) |
| 18 months | 81 | 122.0 (17.0) | 71 | 120.1 (11.6) | 75 | 121.3 (13.2) |
| 30 months | 76 | 122.0 (13.0) | 66 | 120.7 (13.3) | 73 | 122.0 (14.7) |
| Diastolic blood pressure (mmHg) | ||||||
| Baseline | 101 | 76.9 (7.9) | 100 | 76.5 (7.8) | 100 | 77.0 (8.2) |
| 6 months | 87 | 75.8 (8.7) | 88 | 75.6 (9.0) | 91 | 75.6 (8.4) |
| 18 months | 81 | 76.0 (9.1) | 71 | 75.6 (7.8) | 75 | 74.8 (9.6) |
| 30 months | 76 | 75.7 (7.7) | 66 | 74.8 (8.4) | 73 | 74.7 (8.8) |
| Total cholesterol (mL/dL) | ||||||
| Baseline | 100 | 196.8 (36.8) | 99 | 200.4 (37.4) | 100 | 200.4 (43.7) |
| 6 months | 86 | 199.6 (41.8) | 88 | 204.7 (36.9) | 92 | 192.0 (45.1) |
| 18 months | 81 | 200.0 (32.7) | 72 | 211.7 (35.0) | 74 | 198.7 (39.9) |
| 30 months | 73 | 201.7 (33.5) | 66 | 210.5 (35.8) | 71 | 196.6 (40.8) |
| HDL (mL/dL) | ||||||
| Baseline | 101 | 48.5 (10.6) | 99 | 50.5 (13.2) | 100 | 49.8 (14.6) |
| 6 months | 86 | 53.0 (11.7) | 88 | 53.7 (11.3) | 92 | 50.0 (13.0) |
| 18 months | 81 | 56.1 (12.5) | 72 | 56.6 (11.3) | 74 | 54.6 (11.0) |
| 30 months | 73 | 56.1 (10.8) | 66 | 58.5 (14.8) | 71 | 54.1 (12.0) |
| LDL (mL/dL) | ||||||
| Baseline | 101 | 121.7 (32.4) | 98 | 124.8 (32.5) | 100 | 122.2 (35.3) |
| 6 months | 86 | 122.8 (34.4) | 88 | 127.7 (32.4) | 92 | 116.9 (37.0) |
| 18 months | 80 | 117.5 (30.0) | 71 | 129.2 (29.6) | 74 | 119.5 (36.5) |
| 30 months | 73 | 119.3 (29.9) | 64 | 126.3 (29.7) | 71 | 116.0 (35.1) |
| Triglycerides (mL/dL) | ||||||
| Baseline | 101 | 134.7 (68.6) | 99 | 129.6 (87.5) | 100 | 141.6 (69.2) |
| 6 months | 86 | 118.8 (60.3) | 88 | 116.7 (53.9) | 92 | 125.6 (63.0) |
| 18 months | 81 | 136.0 (76.4) | 72 | 129.4 (75.1) | 74 | 122.9 (55.4) |
| 30 months | 73 | 131.8 (63.9) | 66 | 128.9 (72.7) | 71 | 132.7 (60.2) |
| Fasting glucose (mL/dL) | ||||||
| Baseline | 101 | 101.7 (15.5) | 99 | 102.0 (22.2) | 100 | 99.4 (14.2) |
| 6 months | 86 | 87.7 (14.5) | 88 | 100.9 (21.4) | 92 | 99.0 (15.8) |
| 18 months | 81 | 97.7 (11.5) | 72 | 96.3 (12.2) | 74 | 97.7 (14.2) |
| 30 months | 73 | 99.6 (12.2) | 66 | 100.5 (19.9) | 70 | 97.7 (16.5) |
Note: 6, 18, and 30 months corresponded to the end of phases 1, 2, and 3, respectively.
Linear mixed modela tests of pairwise group comparisons of estimated difference in change by phase of intervention.
| Outcome | Phase 1 | Phase 2 | Phase 3 | |||
|---|---|---|---|---|---|---|
| Baseline to 6 months | 6 months to 18 months | 18 months to 30 months | ||||
| Pairwise comparison |
| Estimated mean difference (95% CI) |
| Estimated mean difference (95% CI) |
| Estimated mean difference (95% CI) |
| Body weight (kg)c | ||||||
| WO versus WD | 0.138 | 0.9 (−0.8 to 2.7) | 0.360 | 0.2 (−1.1 to 1.6) | 0.268 | −0.4 (−1.8 to 0.9) |
| WO versus WE | 0.188 | −0.8 (−2.5 to 0.9) | 0.411 | −0.2 (−1.5 to 1.2) | 0.444 | −0.1 (−1.4 to 1.2) |
| WD versus WE | 0.047 | −1.7 (−3.4 to 0.0) | 0.563 | −0.4 (−1.7 to 1.0) | 0.632 | 0.3 (−1.0 to 1.7) |
| Waist circumference (cm)c | ||||||
| WO versus WD | 0.070 | 1.6 (−0.5 to 3.7) | 0.497 | −0.01 (−1.5 to 1.4) | 0.479 | −0.04 (−1.5 to 1.4) |
| WO versus WE | 0.461 | 0.1 (−2.0 to 2.2) | 0.441 | −0.1 (−1.5 to 1.3) | 0.463 | −0.1 (1.5 to 1.3) |
| WD versus WE | 0.164 | −1.5 (−3.5 to 0.6) | 0.891 | −0.1 (−1.6 to 1.4) | 0.970 | −0.03 (−1.5 to 1.4) |
| Kcal intake daily | ||||||
| WO versus WD | 0.105 | −96.9 (−248.7 to 55.0) | 0.473 | −4.7 (−138.8 to 129.3) | 0.134 | −67.3 (−186.5 to 52.0) |
| WO versus WE | 0.139 | −83.5 (−234.6 to 67.7) | 0.289 | −37.6 (−170.5 to 95.2) | 0.183 | 53.6 (−62.8 to 170.0) |
| WD versus WE | 0.861 | 13.4 (−137.2 to 164.1) | 0.633 | −32.9 (−168.4 to 102.6) | 0.050 | 120.9 (0.0 to 241.8) |
| Weekly minutes ≥ moderate intensity activity (Actigraph) | ||||||
| WO versus WD | 0.497 | −0.2 (−38.3 to 37.9) | 0.271 | 10.9 (−24.2 to 46.0) | 0.373 | −6.0 (−42.2 to 30.2) |
| WO versus WE | 0.332 | −8.3 (−46.0 to 29.3) | 0.270 | 10.9 (−24.1 to 45.9) | 0.240 | 12.9 (−23.0 to 48.7) |
| WD versus WE | 0.672 | −8.2 (−46.1 to 29.8) | 0.999 | 0.02 (−35.6 to 35.7) | 0.313 | 18.9 (−17.9 to 55.6) |
| Weekly minutes ≥ moderate intensity activity (BRFSS)c | ||||||
| WO versus WD | 0.207 | −30.6 (−104.2 to 43.0) | 0.055 | 51.6 (−11.7 to 114.8) | 0.344 | −10.1 (−59.8 to 39.6) |
| WO versus WE | 0.427 | 6.8 (−66.4 to 80.0) | 0.336 | 13.5 (−49.1 to 76.1) | 0.288 | −13.8 (−62.5 to 34.8) |
| WD versus WE | 0.314 | 37.4 (−35.6 to 110.5) | 0.238 | −38.1 (−101.4 to 25.2) | 0.885 | −3.7 (−54.2 to 46.7) |
| Systolic blood pressure (mmHg)c | ||||||
| WO versus WD | 0.209 | 1.3 (−1.9 to 4.6) | 0.318 | −0.9 (−4.8 to 2.9) | 0.419 | 0.4 (−3.3 to 4.0) |
| WO versus WE | 0.137 | −1.8 (−5.1 to 1.4) | 0.395 | −0.5 (−4.3 to 3.3) | 0.310 | 0.9 (−2.7 to 4.5) |
| WD versus WE | 0.054 | −3.2 (−6.4 to 0.1) | 0.833 | 0.4 (−3.4 to 4.3) | 0.782 | 0.5 (−3.2 to 4.2) |
| Diastolic blood pressure (mmHg)c | ||||||
| WO versus WD | 0.317 | 0.5 (−1.4 to 2.3) | 0.431 | −0.2 (−2.4 to 2.0) | 0.468 | −0.1 (−2.2 to 2.1) |
| WO versus WE | 0.216 | −0.7 (−2.6 to 1.1) | 0.215 | −0.9 (−3.1 to 1.3) | 0.342 | 0.4 (−1.7 to 2.5) |
| WD versus WE | 0.205 | 1.2 (−3.0 to 0.7) | 0.548 | −0.7 (−2.9 to 1.6) | 0.639 | 0.5 (−1.7 to 2.7) |
| Total cholesterol (mL/dL) | ||||||
| WO versus WD | 0.473 | 0.4 (−10.2 to 11.0) | 0.094 | 7.2 (−3.5 to 17.9) | 0.154 | −4.3 (−12.7 to 4.0) |
| WO versus WE | 0.026 | −10.4 (−20.8 to 0.1) | 0.076 | 7.7 (−2.8 to 18.3) | 0.116 | −5.0 (−13.2 to 3.2) |
| WD versus WE | 0.043 | −10.8 (−21.2 to −0.3) | 0.918 | 0.6 (−10.2 to 11.3) | 0.873 | −0.7 (−9.2 to 7.8) |
| HDL (mL/dL) | ||||||
| WO versus WD | 0.060 | −2.2 (−5.0 to 0.6) | 0.365 | 0.4 (−2.1 to 3.0) | 0.147 | 1.4 (−1.2 to 4.1) |
| WO versus WE | 0.002d | −4.0 (−6.8 to −1.3) | 0.062 | 2.0 (−0.5 to 4.4) | 0.273 | −0.8 (−3.4 to 1.8) |
| WD versus WE | 0.196 | −1.8 (−4.6 to 0.9) | 0.241 | 1.5 (−1.0 to 4.0) | 0.105 | −2.2 (−4.9 to 0.5) |
| LDL (mL/dL) | ||||||
| WO versus WD | 0.350 | 1.6 (−6.7 to 10.0) | 0.081 | 6.1 (−2.5 to 14.8) | 0.064 | −5.6 (−12.7 to 1.6) |
| WO versus WE | 0.079 | −5.9 (−14.1 to 2.3) | 0.023 | 8.7 (0.2 to 17.2) | 0.029 | −6.8 (−13.8 to 0.2) |
| WD versus WE | 0.072 | −7.5 (−15.8 to 0.7) | 0.561 | 2.6 (−6.1 to 11.3) | 0.732 | −1.3 (−8.5 to 6.0) |
| Triglycerides (mL/dL) | ||||||
| WO versus WD | 0.370 | 3.1 (−15.0 to 21.1) | 0.429 | −1.4 (−16.6 to 13.8) | 0.337 | 3.2 (−11.9 to 18.4) |
| WO versus WE | 0.477 | 0.5 (−17.4 to 18.4) | 0.028 | −14.7 (−29.8 to 0.3) | 0.023 | 15.3 (0.4 to 30.3) |
| WD versus WE | 0.782 | −2.5 (−20.4 to 15.4) | 0.089 | −13.3 (−28.7 to 2.0) | 0.123 | 12.1 (−3.3 to 27.5) |
| Fasting glucose (mL/dL) | ||||||
| WO versus WD | 0.081 | 2.7 (−1.1 to 6.5) | 0.141 | −2.0 (−5.7 to 1.7) | 0.360 | 0.6 (−2.9 to 4.2) |
| WO versus WE | 0.024 | 3.8 (0.1 to 7.6) | 0.195 | −1.6 (−5.2 to 2.0) | 0.046 | −3.0 (−6.4 to 0.5) |
| WD versus WE | 0.565 | 1.1 (−2.7 to 4.9) | 0.827 | 0.4 (−3.3 to 4.1) | 0.047 | −3.6 (−7.2 to 0.0) |
aDirect maximum likelihood methods were used to analyze a mixed-effects repeated-measures model (random intercept, unstructured variance/covariance matrix), with tests of pairwise contrasts of group differences in the change in outcome from beginning to end of each phase.
bComparisons of web-based with discussion board (WD) and web-based with email counseling (WE) with web-based only (WO) were one-tailed and WD with WE were two-tailed, each tested at α = .017.
cAnalyses also included data collected at 3, 12, and 24 months, but comparisons focused on group differences in change from the beginning to the end of each phase.
dSignificant effect was not in hypothesized direction.
Estimated proportiona meeting criteria in each intervention group, tests of pairwise group comparisonsb, and odds ratios at 6 months, 18 months, and 30 months.
| Outcome | Estimated proportions | WO versus WD | WO versus WE | WD versus WE | |||||
|---|---|---|---|---|---|---|---|---|---|
| WO | WD | WE |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) | |
| Weight loss ≥ 5% of baseline | |||||||||
| 6 months | .42 | .38 | .51 | 0.290 | 1.2 (0.7 to 2.2) | 0.117 | 0.7 (0.4 to 1.3) | 0.078 | 1.7 (0.9 to 3.0) |
| 18 months | .31 | .31 | .42 | 0.476 | 1.0 (0.5 to 2.1) | 0.066 | 0.6 (0.3 to 1.2) | 0.158 | 1.7 (0.8 to 3.4) |
| 30 months | .32 | .31 | .40 | 0.442 | 1.1 (0.5 to 2.2) | 0.135 | 0.7 (0.4 to 1.3) | 0.239 | 1.5 (0.8 to 3.0) |
| Weight loss ≥ 10% of baseline | |||||||||
| 6 months | .24 | .19 | .29 | 0.297 | 1.3 (0.6 to 2.7) | 0.206 | 0.8 (0.4 to 1.5) | 0.120 | 1.7 (0.9 to 3.4) |
| 18 months | .17 | .17 | .18 | 0.433 | 1.1 (0.5 to 2.5) | 0.311 | 0.8 (0.4 to 1.8) | 0.528 | 1.3 (0.6 to 3.0) |
| 30 months | .29 | .20 | .20 | 0.326 | 0.8 (0.3 to 2.0) | 0.185 | 0.7 (0.3 to 1.5) | 0.700 | 1.2 (0.5 to 2.7) |
| 20–35% calories from fat | |||||||||
| 6 months | .53 | .38 | .56 | 0.023 | 1.8 (1.0 to 3.4) | 0.341 | 0.9 (0.5 to 1.6) | 0.017 | 2.1 (1.1 to 3.8) |
| 18 months | .48 | .32 | .45 | 0.019 | 1.9 (1.0 to 3.6) | 0.346 | 1.1 (0.6 to 2.2) | 0.109 | 1.7 (0.9 to 3.3) |
| 30 months | .38 | .29 | .46 | 0.096 | 1.5 (0.8 to 2.9) | 0.151 | 0.7 (0.4 to 1.3) | 0.021 | 2.1 (1.1 to 4.0) |
| ≥150 minutes weekly moderate or greater intensity activity (Actigraph) | |||||||||
| 6 months | .78 | .81 | .75 | 0.279 | 0.8 (0.4 to 1.7) | 0.361 | 1.1 (0.6 to 2.3) | 0.352 | 0.7 (0.3 to 1.5) |
| 18 months | .79 | .71 | .71 | 0.138 | 1.5 (0.7 to 3.1) | 0.131 | 1.5 (0.7 to 3.3) | 0.940 | 1.0 (0.5 to 1.9) |
| 30 months | .74 | .68 | .64 | 0.236 | 1.3 (0.6 to 2.7) | 0.093 | 1.6 (0.8 to 3.1) | 0.591 | 0.8 (0.4 to 1.7) |
| ≥150 minutes weekly moderate or greater intensity activity (BRFSS) | |||||||||
| 6 months | .44 | .36 | .42 | 0.159 | 1.4 (0.7 to 2.7) | 0.403 | 1.1 (0.6 to 2.0) | 0.397 | 1.3 (0.7 to 2.4) |
| 18 months | .34 | .32 | .36 | 0.443 | 1.1 (0.5 to 2.2) | 0.361 | 0.9 (0.5 to 1.7) | 0.623 | 1.2 (0.6 to 2.4) |
| 30 months | .31 | .32 | .27 | 0.444 | 1.0 (0.5 to 1.9) | 0.286 | 1.2 (0.6 to 2.4) | 0.489 | 0.8 (0.4 to 1.6) |
Notes. WO is web-based only group, WD is web-based with peer-led discussion group, and WE is web-based with professional email counseling.
aProportions estimated from the 20 imputed datasets.
bGeneralized estimating equations (GEEs) were used with multiply imputed dataset to fit a model to all three times, incorporating tests of pairwise comparisons of groups on the proportion meeting criteria at end of each phase.
cWO versus WD and WO versus WE are one-tailed tests to match hypotheses, and WD versus WE is two-tailed, each tested at α = .017.
Dosage of web-delivered content as assessed by women's logins at time points when new intervention content was posted by intervention phase.
| Dosagea | Web-based | Web-based | Web-based | |||
|---|---|---|---|---|---|---|
| Dosage operationally defined when women logged into website during time points when new content was available, regardless of number of logins |
| % |
| % |
| % |
|
| ||||||
| Phase 1b, 26 segments of new content posted over 26 weeks | ||||||
| 100% dosage (26 segments) | 16 | 18.4% | 11 | 12.5% | 12 | 13.0% |
| 75–99% dosage (20–25 segments) | 21 | 24.1% | 32 | 36.4% | 30 | 32.6% |
| 50–74% dosage (13–19 segments) | 23 | 26.4% | 15 | 17.0% | 22 | 23.9% |
| 25–46% dosage (7–12 segments) | 14 | 16.1% | 16 | 18.2% | 12 | 13.0% |
| 1–25% dosage (1–6 segments) | 13 | 14.9% | 13 | 14.8% | 15 | 16.3% |
| 0% no dosage (0 segments) | 0 | 0.0% | 1 | 1.1% | 1 | 1.1% |
| Total number of phase 1 completers | 87 | 88 | 92 | |||
| Phase 2c, 26 segments of new content posted over 1 year | ||||||
| 100% dosage (26 segments) | 3 | 3.7% | 0 | 0.0% | 2 | 2.6% |
| 75–99% dosage (20–25 segments) | 13 | 16.0% | 9 | 12.5% | 15 | 19.5% |
| 50–74% dosage (13–19 segments) | 6 | 7.4% | 8 | 11.1% | 9 | 11.7% |
| 25–46% dosage (7–12 segments) | 14 | 17.3% | 10 | 13.9% | 8 | 10.4% |
| 1–25% dosage (1–6 segments) | 28 | 34.6% | 28 | 38.9% | 29 | 37.7% |
| 0% no dosage (0 segments) | 17 | 21.0% | 17 | 23.6% | 14 | 18.2% |
| Total number of phase 2 completers | 81 | 72 | 77 | |||
| Phase 3d, 9 segments of new content posted over 1 year | ||||||
| >55.5%–100% dosage (6–9 segments) | 16 | 21.1% | 17 | 25.3% | 15 | 20.5% |
| 1–55.5% dosage (1–5 segments) | 54 | 71.0% | 40 | 59.7% | 54 | 73.97% |
| 0% no dosage (0 segments) | 6 | 7.9% | 10 | 14.9% | 5 | 6.8% |
| Total number of phase 3 completers | 76 | 67 | 73 | |||
|
| ||||||
| Phase 1, 26 new discussion board primers posted over 26 weeks | ||||||
| 100% dosage (26 primers) | 8 | 9.1% | ||||
| 75–99% dosage (20–25 primers) | 19 | 21.6% | ||||
| 50–74% dosage (13–19 primers) | 13 | 14.8% | ||||
| 25–46% dosage (7–12 primers) | 20 | 22.7% | ||||
| 1–25% dosage (1–6 primers) | 23 | 26.1% | ||||
| 0% no dosage (0 primers) | 5 | 5.7% | ||||
| Phase 2, 18 new discussion board primers posted over 1 year | ||||||
| 50–100% dosage (9–18 primers) | 16 | 22.2% | ||||
| 1–49% dosage (1–8 primers) | 34 | 47.2% | ||||
| 0% no dosage (0 primers) | 22 | 30.5% | ||||
| Phase 3, views and posts | ||||||
| One or more views | 28 | 41.8% | ||||
| Did not view board in phase 3 | 39 | 58.2% | ||||
| One or more posts | 10 | 14.9% | ||||
| Did not post on board in phase 3 | 57 | 79.2% | ||||
aDosage was operationally defined as met when women logged on to website during time points when new content was made available, regardless of the number of logins during or between that time point. Note that women received an email prompt when new content was made available.
bPhase 1 (baseline to 6 months) offered new content weekly for a total of 26 segments of new content.
cPhase 2 (6 to 18 months) offered biweekly new content, named “hot topics” as reflected of current news stories, for a total of 26 segments of new content.
dPhase 3 (18 to 30 months) offered new content in form of videos, success stories, and cartoons monthly for months 18 to 24 and bimonthly for months 24 to 30 for a total of 9 segments of new content.
eThe discussion board peer-leader was responsible for posting new discussion topics called primers on the following schedule: phase 1 primers posted weekly for 26 total; phase 2 primers posted biweekly months 6 to 12 and monthly during months 12 to 18 for 18 total; and, phases 1 and 2 dosage reflected logins regardless of whether women posted or viewed posts. At phase 3, women received 3 initial primers yet had access to discussion board throughout the phase. Only the number of views and the number of posts are reported for WD during phase 3.